Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
To achieve global hepatitis C virus (HCV) elimination by 2030, 80% of the ~71 million people
with chronic HCV infection will need to be treated, necessitating simplification of treatment
delivery and associated laboratory monitoring without compromising efficacy or safety. The
COVID-19 pandemic has further highlighted the need for innovative models of health care
delivery that minimize face-to-face patient-provider contact. The purpose of this study was
to evaluate the feasibility, safety, and efficacy of a minimal monitoring (MINMON) strategy
to deliver interferon- and RBV-free, pan-genotypic DAA therapy to treat active HCV in HCV
treatment naïve participants.
Phase:
Phase 4
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir